CIAM
MYGN icon

Caitong International Asset Management’s Myriad Genetics MYGN Stock Holding History

Caitong International Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33
Closed -$203 – 2888
2025
Q4 		$203 Buy
+33
New +$239 ﹤0.01% 1618
2025
Q2 		– Sell
-295
Closed -$2.62K – 2303
2025
Q1 		$2.62K Buy
+295
New +$3.54K ﹤0.01% 1243

Other funds holding MYGN

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Glenview Capital Management
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Caitong International Asset Management's MYGN Position: Q1 2026 in Review

Caitong International Asset Management sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 33 shares — an estimated $203 sold.

Caitong International Asset Management first reported a position in MYGN in Q1 2025 and held it in 2 quarters. The position peaked at $2.62K in Q1 2025. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Caitong International Asset Management reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 33 Myriad Genetics shares in Q1 2026, an estimated $203.
  • Caitong International Asset Management first reported a position in Myriad Genetics in Q1 2025 and held it in 2 quarters.
  • Caitong International Asset Management's Myriad Genetics position peaked at $2.62K in Q1 2025.
  • 203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.